GLP-1 Receptor Agonists for Patients on Aromatase Inhibitor Therapy

Introduction to GLP-1 Receptor Agonists

The American Association of Clinical Endocrinologists recommends considering GLP-1 receptor agonists for breast cancer patients on aromatase inhibitors with insulin resistance or significant weight gain 2

GLP-1 receptor agonists improve insulin sensitivity through multiple mechanisms, including promoting β-cell proliferation and protecting against apoptosis, which helps preserve pancreatic function compromised by aromatase inhibitor-induced insulin resistance 2
Tirzepatide's dual GIP-GLP-1 receptor activation produces synergistic effects on insulin response and glucagon suppression, leading to improved glycemic control 2

Semaglutide 2.4mg weekly achieves 14.9-17.4% total body weight loss over 52-72 weeks, directly counteracting aromatase inhibitor-induced weight gain 2
Tirzepatide 15mg weekly demonstrates superior weight loss of 20.9%, with 6.5% additional weight loss compared to semaglutide at 72 weeks, providing greater metabolic benefits 2

Semaglutide reduces the composite incidence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 26% (HR 0.74, 95% CI 0.58-0.95) in the SUSTAIN 6 trial, providing critical cardiovascular benefits for breast cancer patients at elevated cardiovascular risk 3
The American Heart Association acknowledges the cardioprotective effects of GLP-1 receptor agonists, which are mediated through improved myocardial substrate utilization, anti-inflammatory and anti-atherosclerotic effects, reduced myocardial ischemia injury, lower systemic and pulmonary vascular resistance, and improved lipid profiles 2

The National Comprehensive Cancer Network recommends starting GLP-1 receptor agonists in breast cancer patients on aromatase inhibitors who have a BMI ≥27 with weight-related comorbidities or BMI ≥30, evidence of insulin resistance, or significant weight gain since starting aromatase inhibitor therapy 2
Initial assessment should include baseline weight, BMI, waist circumference, fasting glucose, HbA1c, lipid panel, blood pressure, and bone density, as recommended by the Journal of the National Comprehensive Cancer Network 1

The American Association of Clinical Endocrinologists recommends tirzepatide as the first-line treatment for greatest metabolic benefit, with a starting dose of 2.5mg weekly for 4 weeks, increasing to 5mg weekly, and titrating to 10mg, then 15mg weekly based on response and tolerability 2
Semaglutide 2.4mg is recommended as a second-line treatment if tirzepatide is unavailable or not tolerated, with a starting dose of 0.25mg weekly for 4 weeks, increasing to 0.5mg weekly, 1.0mg weekly, and 1.7mg weekly, reaching a maintenance dose of 2.4mg weekly after 16 weeks 2

Gastrointestinal effects, such as nausea, vomiting, and diarrhea, are the most common side effects, but are typically mild-to-moderate and decrease over time, as noted by the Anaesthesia journal 3
Slow titration is essential for increasing tolerability, and effects are dose-dependent and more frequent with short-acting than long-acting drugs, according to the Praxis Medical Insights 2

GLP-1 receptor agonists can be started at any point during aromatase inhibitor therapy, without drug-drug interactions, as stated by the Journal of the National Comprehensive Cancer Network 1
The Annals of Oncology notes that GLP-1 receptor agonists do not interfere with bone-protective therapies, such as bisphosphonates or denosumab, and recommends continuing these therapies as recommended for aromatase inhibitor patients 4

Weight loss must be combined with resistance training to preserve lean body mass, as GLP-1 receptor agonists can cause lean body mass loss without concurrent physical activity, as warned by the Praxis Medical Insights 2
Long-term use is required, as significant weight regain occurs after cessation of semaglutide, and these medications must be used lifelong in conjunction with lifestyle changes, according to the Praxis Medical Insights 2